BioSpace News Archive

Denali Therapeutics Inc. today announced its participation at MPS 2021, the 16 th Annual International Symposium of MPS and Related Diseases

Emmaus Life Sciences, Inc. announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).

In the largest clinical study of its kind to date, a team of scientists at Stanford University confirmed a new model of mental health treatment that uses artificial intelligence therapy is significantly effective at reducing symptoms of depression and anxiety.

Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the company’s NUsurface® Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy.

Grit Bio today announced the closing of a Series A+ financing. The financing was led by GL Ventures, the venture capital unit of Hillhouse Group, with participation from Apricot Capital and Junshi Biosciences

Synexis® LLC, a pioneer in microbial reduction and sole developer of patented technology that creates Dry Hydrogen Peroxide (DHP™) for occupied spaces, today announced that DHP™ begins reducing viral load in larger indoor spaces (total volume 5,940 ft3) in 45 minutes, and significantly reduces surface levels of infectious SARS-CoV-2 virus in 120 minutes of continuous treatment

Today, the U.S. Food and Drug Administration fully approved Tanovea (rabacfosadine injection) to treat lymphoma in dogs. Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs.

ResMed announced it plans to release financial and operational results for the fourth quarter of fiscal year 2021 on Thursday, August 5, 2021, after the New York Stock Exchange closes.

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 77,800 shares of its common stock with an exercise price of $8.77, which is equal to the closing price of Gritstone’s common stock on July 12, 2021, the grant date of the awards.

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced the appointment of Jennifer Moses, CPA to the Company’s Board of Directors and as Chair of the Audit Committee.